查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球年龄相关性黄斑变性市场
市场调查报告书
商品编码
1143388

2022-2029 年全球年龄相关性黄斑变性市场

Global Age Related Macular Degeneration Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

到 2021 年，与年龄相关的黄斑变性市场规模估计为 98.4 亿美元，在预测期间（2022-2029 年）以 6.90% 的复合年增长率增长。

年龄相关性黄斑变性包括治疗急性和慢性伤口的产品，例如溃疡、烧伤和手术后伤口。薄膜和泡沫敷料、水凝胶、藻酸盐和水胶体等产品可将水分保留在伤口中，以促进癒合而不阻塞伤口。这个市场为慢性伤口患者提供了一种解决方案，提供易于获得且价格合理的产品，方便他们使用。与年龄相关的黄斑变性管理市场报告还涵盖了各种竞争技术，例如先进的伤口敷料技术、有害压力伤口治疗 (NPWT)、生物製剂/生物活性产品和高压氧治疗设备。

市场动态

市场增长的主要驱动力是全球与年龄相关的眼病患病率不断上升、老年人口不断增长、技术进步以及治疗报销带来的好处。

全球与年龄相关的眼病增加和老龄化社会的进步预计将推动市场增长

根据世界卫生组织的数据，2020 年全球约有 1.96 亿人将受到老年性黄斑变性的影响，其中超过 1040 万人将遭受中度至重度视力障碍。此外，联合国经济和社会事务部的数据显示，到 2020 年，65 岁及以上的人口将达到约 7.27 亿。但是，据说到2050年老年人口将增加约200万。目前，只有少数药物，主要是抗 VEGF 药物，被批准用于治疗老年性黄斑变性。抗VEGF药物需要反复眼内註射，不方便、繁重，导致治疗不依从。为了克服这一挑战，主要参与者正在开髮长效抗 VEGF 药物和促进持续给药的玻璃体植入物。 Beov 和 Babismo 等长效抗 VEGF 药物的推出预计将在预测期内促进市场增长。

高昂的治疗成本是阻碍市场增长的主要因素之一

这个市场的主要製约因素是治疗成本。一次注射费用高达 775.3 美元，大多数患者每年需要大约 8 次注射。然而，在几项研究中，与雷珠单抗和阿柏西普 IVAN 试验（由英国卫生部资助）相比，第三种非常相似的药物贝伐单抗 (Avastin) 单次注射成本仅为 27.14 美元。显示具有相似的效果。因此，贝伐单抗在美国和澳大利亚等其他国家被广泛用于 AMD，在英国被广泛用于导致新生血管形成的其他疾病（如糖尿病视网膜病变）。然而，除了在英国没有获得治疗 AMD 的许可外，这种更便宜的替代方案并未在 NHS 中广泛用于治疗这种常见疾病。

COVID-19 影响分析

在 COVID-19 流行初期，AMD 治疗的错过或延迟随访导致不依从性，从而对市场产生负面影响。例如，2020 年 7 月，霍夫曼罗氏 (Hoffman-Roche) 的 AMD 药物 Lucentis 第二季度销售额增长缓慢，同比增长 4.01 亿美元。

全球年龄相关性黄斑变性市场 - 行业分析

全球年龄相关性黄斑变性市场基于波特五力、监管分析、报销分析、供应链分析、定价分析和技术进步等各种行业因素对市场进行了深入分析。 .

细分分析

湿性 AMD 细分市场有望在全球老年性黄斑变性市场占据最大市场份额

湿性 AMD 病例占全球因黄斑变性导致的所有视力丧失病例的 10-15% 以上。 Lucentis、Eilea 和 Beov 是治疗湿性老年性黄斑变性的有效药物。诺华的长效抗 VEGF 药物 Beov 于 2019 年 10 月获得美国 FDA 批准。然而，该药物具有不利的副作用，例如视网膜血管炎，这将限制其更广泛的吸收。

此外，2021 年 9 月，Biogen 和三星 Bioepis 宣布，品牌名称为“BYOOVIZ”的 Lucentis 生物仿製药版本将用于湿性 AMD、近视脉络膜新生血管和视网膜静脉阻塞的测试。已获得美国 FDA 批准作为治疗剂在美国，由于申请了附加保护证书，于2022年6月发布。此外，包括英国在内的欧盟国家已于2021年8月获得批准。

按地区分析

北美在全球老年性黄斑变性市场中占有最大的市场份额

全球老年性黄斑变性市场由北美主导，预计在预测期内将保持其地位。根据美国眼科学会的数据，北美约有 1500 万人患有 AMD。此外，在 Beaver Dam 眼科研究中，进行性 ARMD 的患病率为 1.6%，其中 1.2% 的眼睛出现湿状，0.6% 的眼睛出现地理性萎缩。该队列涵盖了 4,926 名年龄在 43 至 86 岁之间的人。在弗雷明汉眼科研究中发现了类似的患病率数据，该研究报告称，52 岁及以上人群的湿性 ARMD 患病率为 1.5%。年龄相关性黄斑变性的患病率在 75 岁以上人群中急剧增加。

值得关注的主要公司

诺华公司：

概述 Novartis AG 是一家瑞士跨国製药公司，总部位于瑞士巴塞尔。我们通过两个部门运作。它分为两个部门：Innovative Pharmaceuticals 和 Sandoz。创新药物部门由两个业务部门组成，诺华製药，包括诺华基因治疗和诺华肿瘤学，将创新的专利药物商业化，以改善患者和医疗保健专业人员的健康。我在这里。作为仿製药和生物仿製药的全球领导者，山德士正在开拓新方法，以增加世界各地人们获得优质药物的机会。

产品组合：Beovu (brolucizumab) - Beovu (brolucizumab) 是欧洲唯一获批的用于湿性 AMD 的抗 VEGF 治疗药物。

本报告提供了近 45+ 个市场数据表、40+ 个图表和 180 页有关全球老年性黄斑变性市场的信息。待办。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
  • 驱动程序
    • 全球与年龄相关的眼病和老龄化人口增加
    • 技术进步
    • 推出用于治疗老年性黄斑变性 (AMD) 的新产品
  • 约束因素
    • 可供选择的治疗方法
    • 昂贵的医疗费用
  • 商机
  • 影响分析

第5章产业要素

  • 波特的五种力量
  • 监管机构分析
  • 供应链分析
  • 报销分析
  • 管道分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • 对 COVID-19 市场的分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按药物类型

  • Lucentis
  • 艾莉亚
  • 阿瓦斯汀
  • 其他

第 8 章按疾病类型

  • 干性 AMD
  • 湿式 AMD

第 9 章治疗

  • 抗血管内皮细胞生长因子注射疗法
  • 光动力疗法
  • 激光手术
  • 抗生素滴注
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 12 章公司简介

  • 诺华
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Bayer
  • Roche
  • Bausch & Lomb
  • Allergan
  • Iconic Therapeutics
  • Neurotech Pharmaceuticals
  • Regeneron Pharmaceuticals Inc
  • Alcon
  • Santen Pharmaceutical

第13章 全球年龄相关性黄斑变性市场-DataM

简介目录
Product Code: DMPH114

Market Overview

Age-Related Macular Degeneration Market size was valued US$ 9.84 billion in 2021 and is estimated to reach US$ YY billion by 2029, growing at a CAGR of 6.90% during the forecast period (2022-2029).

Age-related macular degeneration comprises products that treat acute and chronic wounds, such as ulcers, burns, and post-operative wounds. The products, such as film and foam dressings, hydrogels, alginates, and hydrocolloids, keep the damage hydrated to encourage healing without occluding the wound. The market offers solutions to patients suffering from chronic wounds by providing them with readily reachable and priced products that can be used at their convenience. The Age-Related Macular Degeneration management market report also covers various competing technologies, such as advanced wound dressing technologies, harmful pressure wound therapies (NPWT), biologics/bioactive products, and hyperbaric oxygen therapy devices.

Market Dynamics

The growth of the market is majorly driven by growing age-related eye diseases across the world, growing aged population, advancements in technology, and reimbursement benefits for treatment are the major factors driving the growth of this market

Growing age-related eye diseases across the world, growing aged population are expected to drive market growth

According to the WHO, globally, around 196 million people were affected by age-related macular degeneration in 2020, including over 10.4 million moderate-to-severe vision impairment cases. Moreover, the United Nations Department of Economic and Social Affairs data revealed that the aged population of 65 years and above was around 727 million in 2020. However, by 2050, the geriatric population will increase approximately 2 million. Only a few drugs, mainly anti-VEGFs, are currently approved to treat age-related macular degeneration. Anti-VEGF drugs require repetitive and inconvenient intraocular injections, which increases the burden and results in non-adherence to treatment. To overcome this challenge, key players are developing longer-acting anti-VEGFs and vitreous implants that facilitate the sustained delivery of drugs. The introduction of long-acting anti-VEGF, such as Beovu and Vabysmo, is expected to boost the market growth over the forecast period.

The high cost associated with the treatment is one of the major factors hindering the growth of the market

The main restrain of this market is the treatment cost. Each injection costs up to $775.3, and most patients require around eight injections annually. However, in several studies, a third very similar drug, bevacizumab (Avastin), which costs only $27.14 per injection, had similar efficacy to ranibizumab and aflibercep IVAN trial (funded by the UK Department of Health). As a result, bevacizumab is widely used in other countries, including the USA and Australia, for AMD and in the UK for other conditions that cause neovascularisation (e.g., diabetic retinopathy). However, apart from not being licensed for AMD in the UK, this cheaper alternative is not used widely in the NHS for this common condition.

COVID-19 Impact Analysis

During the early phase of the COVID-19 pandemic, the market was negatively impacted due to missed or delays in follow-up for AMD treatment leading to non-adherence to medications. For example, in July 2020, Hoffman Roche witnessed low growth in the sale of its AMD drug Lucentis to USD 401 million in the second quarter over the same period in the previous year.

Global Age-Related Macular Degeneration Market - Industry Analysis

The global age-related macular degeneration market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, reimbursement analysis, supply chain analysis, pricing analysis, technological advancements etc.

Segment Analysis

Wet AMD segment is expected to hold the largest market share in global age-related macular degeneration market

Wet AMD cases account for more than 10-15% of macular degeneration-related vision loss cases worldwide. Lucentis, Eylea, and Beovu are effective drugs for treating wet age-related macular degeneration. Novartis' Beovu, a long-acting anti-VEGF, was approved by the U.S. FDA in October 2019. Although, the unfavourable side effects of this drug, such as retinal vasculitis, will limit its broader uptake.

Furthermore, in September 2021, Biogen Inc. and Samsung Bioepis Co., Ltd. obtained U.S. FDA approval for their biosimilar version of Lucentis under the brand name of BYOOVIZ for treating wet AMD, myopic choroidal neovascularization, and retinal vein occlusion. However, the product was launched in the U.S. on June 2022, owing to applicable supplementary protection certificates. In addition, the product received approval in EU countries, including the U.K., in August 2021.

Geographical Analysis

North America region holds the largest market share in the global age-related macular degeneration market

North America dominated the global age-related macular degeneration market and is expected to retain its position during the forecast period. According to the American Academy of Ophthalmology, around 15 million North Americans live with AMD. Moreover, the prevalence of advanced ARMD in the Beaver Dam Eye Study was 1.6%, with the exudative form being present in one eye 1.2% of the time, and geographic atrophy in one eye 0.6% of the time. This population represented 4,926 people between the ages of 43 to 86 years of age. Similar prevalence data was noted in the Framingham Eye Study, which reported a prevalence of exudative ARMD in those older than 52 years of age of 1.5%. The prevalence of age-related macular degeneration sharply increases in those 75 years or older.

Competitive Landscape

The age-related macular degeneration market is moderately competitive. The key players contributing to the global market's growth include Bayer, Novartis, Roche, Bausch & Lomb, Allergan, Iconic Therapeutics, Neurotech Pharmaceuticals, Regeneron Pharmaceuticals Inc., Alcon, Santen Pharmaceutical. For instance, in June 2021, Mosaic Biosciences and Ocular Therapeutix entered into a research collaboration for the development of a drug to treat patients with dry age-related macular degeneration.

Key Companies to Watch

Novartis AG:

Overview: Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It operates business through two divisions: Innovative medicine, Sandoz. Made up of two business units - Novartis Pharmaceuticals which includes Novartis Gene Therapies, and Novartis Oncology - our Innovative Medicines Division commercializes innovative patented medicines to enhance health outcomes for patients and healthcare professionals. Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people around the world access high-quality medicines.

Product Portfolio: Beovu (brolucizumab) - Beovu (brolucizumab) is the only anti-VEGF treatment approved in Europe for wet AMD.

The global age-related macular degeneration market report would provide an access to an approx. 45+ market data table,, 40+ figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Growing age-related eye diseases across the world, growing aged population
    • 4.2.2. Advancements in technology
    • 4.2.3. The introduction of new products for the treatment of age-related macular degeneration (AMD)
  • 4.3. Restraints
    • 4.3.1. Availability of alternative treatment options
    • 4.3.2. High cost of treatments
  • 4.4. Opportunities
  • 4.5. Impact Analysis

5. Industry Factors

  • 5.1. Porter's Five Forces
  • 5.2. Regulator Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Reimbursement Analysis
  • 5.5. Pipeline analysis
  • 5.6. Pricing Analysis
  • 5.7. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index, By Drug Type
  • 7.2. Lucentis*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Eylea
  • 7.4. Avastin
  • 7.5. Others

8. By Disease Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 8.1.2. Market Attractiveness Index, By Disease Type
  • 8.2. Dry AMD*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Wet AMD

9. By Treatment Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.1.2. Market Attractiveness Index, By Treatment Type
  • 9.2. Injecting Anti-vascular endothelial growth factor*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Photodynamic therapy
  • 9.4. Laser surgery
  • 9.5. Antibiotic drops
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. South America
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Brazil
      • 10.3.6.2. Argentina
      • 10.3.6.3. Rest of South America
  • 10.4. Europe
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Germany
      • 10.4.6.2. The U.K.
      • 10.4.6.3. France
      • 10.4.6.4. Spain
      • 10.4.6.5. Italy
      • 10.4.6.6. Rest of Europe
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East & Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Novartis
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bayer
  • 12.3. Roche
  • 12.4. Bausch & Lomb
  • 12.5. Allergan
  • 12.6. Iconic Therapeutics
  • 12.7. Neurotech Pharmaceuticals
  • 12.8. Regeneron Pharmaceuticals Inc
  • 12.9. Alcon
  • 12.10 Santen Pharmaceutical

LIST NOT EXHAUSTIVE

13. Global Age-Related Macular Degeneration Market - DataM

  • 13.1. Appendix
  • 13.2. About Us
  • 13.3. Contact Us